FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376613426> ?p ?o ?g. }

• W4376613426 endingPage "101417" @default.
• W4376613426 startingPage "101417" @default.
• W4376613426 abstract "The combination of docetaxel (D) with trastuzumab and pertuzumab (T+P) remains the standard first-line in metastatic HER2-positive breast cancer (BC), based on the results of the CLEOPATRA trial. However, all patients (pts) do not benefit equally from this therapy. We explored the association between survival outcomes and initial tumoral response to D+T+P. We performed an exploratory analysis of CLEOPATRA (NCT00567190) using data extracted from the Vivli database (ID:00007856). The primary objective was to assess the overall survival (OS) of pts treated with D+T+P according to their response at the first tumor assessment at 9 weeks. Secondary objective was progression-free survival (PFS). Response was classified as complete (CR), partial (PR), or stable (SD), according to RECIST1.0 based on central review as per original trial. Pts without first tumor assessment were excluded. We performed a log-rank test to compare Kaplan-Meier curves, and uni- and multivariate analysis. We applied Extended Cox Regression Model to consider a possible guarantee-time bias. In D+T+P arm, 362/402 pts were included: 12.7% (46/62) with CR, 67.1% (243/362) with PR, and 20.2% (73/362) with SD. In CR group, 47.8% of pts had de novo disease (61.3% in PR, 43.8% in SD, Fisher’s exact test p=0.015), 69.6% had visceral disease (83.3% in PR, 67.1% in SD, p=0.005), 60.9% were hormone receptor (HR) negative (51.9% in PR, 49.3% in SD, p=NS). After a median (m) follow-up of 4.1 years, pts in CR group had a significantly longer PFS compared to PR or SD (log-rank p<0.001), and a longer OS compared to PR or SD (mOS not reached (NR), 57.3 mo (interquartile (IQR) 32.1-NR) and 43.4 mo (IQR 22-103.5) in the CR, PR, and SD group, respectively, p=0.002). In multivariate analysis, a high body mass index was associated with better OS in SD group (HR=0.93 95%; confidence interval (CI) (0.88-0.99) p=0.023), ECOG ≥1 with worse OS in PR group (HR=1.66 95% CI (1.17-2.36) p=0.005). The outcome benefit of CR was equal in HR- and HR+ tumors, p=NS. Obtaining an early radiological CR with D+T+P confers significantly longer OS and PFS, whereas no difference is observed once compared with PR and SD." @default.
• W4376613426 created "2023-05-17" @default.
• W4376613426 creator A5002113898 @default.
• W4376613426 creator A5014689698 @default.
• W4376613426 creator A5034961078 @default.
• W4376613426 creator A5057851384 @default.
• W4376613426 creator A5072581506 @default.
• W4376613426 creator A5080255285 @default.
• W4376613426 creator A5081663693 @default.
• W4376613426 creator A5082230442 @default.
• W4376613426 creator A5082293621 @default.
• W4376613426 creator A5085649082 @default.
• W4376613426 date "2023-05-01" @default.
• W4376613426 modified "2023-10-18" @default.
• W4376613426 title "228P The impact of initial tumor response to docetaxel, trastuzumab, and pertuzumab on survival outcomes of patients with HER2+ metastatic breast cancer: An exploratory analysis of the CLEOPATRA trial" @default.
• W4376613426 doi "https://doi.org/10.1016/j.esmoop.2023.101417" @default.
• W4376613426 hasPublicationYear "2023" @default.
• W4376613426 type Work @default.
• W4376613426 citedByCount "0" @default.
• W4376613426 crossrefType "journal-article" @default.
• W4376613426 hasAuthorship W4376613426A5002113898 @default.
• W4376613426 hasAuthorship W4376613426A5014689698 @default.
• W4376613426 hasAuthorship W4376613426A5034961078 @default.
• W4376613426 hasAuthorship W4376613426A5057851384 @default.
• W4376613426 hasAuthorship W4376613426A5072581506 @default.
• W4376613426 hasAuthorship W4376613426A5080255285 @default.
• W4376613426 hasAuthorship W4376613426A5081663693 @default.
• W4376613426 hasAuthorship W4376613426A5082230442 @default.
• W4376613426 hasAuthorship W4376613426A5082293621 @default.
• W4376613426 hasAuthorship W4376613426A5085649082 @default.
• W4376613426 hasBestOaLocation W43766134261 @default.
• W4376613426 hasConcept C121608353 @default.
• W4376613426 hasConcept C124952713 @default.
• W4376613426 hasConcept C126322002 @default.
• W4376613426 hasConcept C142362112 @default.
• W4376613426 hasConcept C143998085 @default.
• W4376613426 hasConcept C191093355 @default.
• W4376613426 hasConcept C207103383 @default.
• W4376613426 hasConcept C2522767166 @default.
• W4376613426 hasConcept C2775930923 @default.
• W4376613426 hasConcept C2778068864 @default.
• W4376613426 hasConcept C2779786085 @default.
• W4376613426 hasConcept C2780739268 @default.
• W4376613426 hasConcept C2781164504 @default.
• W4376613426 hasConcept C2781190966 @default.
• W4376613426 hasConcept C3018260909 @default.
• W4376613426 hasConcept C3019894029 @default.
• W4376613426 hasConcept C41008148 @default.
• W4376613426 hasConcept C44249647 @default.
• W4376613426 hasConcept C50382708 @default.
• W4376613426 hasConcept C530470458 @default.
• W4376613426 hasConcept C71924100 @default.
• W4376613426 hasConceptScore W4376613426C121608353 @default.
• W4376613426 hasConceptScore W4376613426C124952713 @default.
• W4376613426 hasConceptScore W4376613426C126322002 @default.
• W4376613426 hasConceptScore W4376613426C142362112 @default.
• W4376613426 hasConceptScore W4376613426C143998085 @default.
• W4376613426 hasConceptScore W4376613426C191093355 @default.
• W4376613426 hasConceptScore W4376613426C207103383 @default.
• W4376613426 hasConceptScore W4376613426C2522767166 @default.
• W4376613426 hasConceptScore W4376613426C2775930923 @default.
• W4376613426 hasConceptScore W4376613426C2778068864 @default.
• W4376613426 hasConceptScore W4376613426C2779786085 @default.
• W4376613426 hasConceptScore W4376613426C2780739268 @default.
• W4376613426 hasConceptScore W4376613426C2781164504 @default.
• W4376613426 hasConceptScore W4376613426C2781190966 @default.
• W4376613426 hasConceptScore W4376613426C3018260909 @default.
• W4376613426 hasConceptScore W4376613426C3019894029 @default.
• W4376613426 hasConceptScore W4376613426C41008148 @default.
• W4376613426 hasConceptScore W4376613426C44249647 @default.
• W4376613426 hasConceptScore W4376613426C50382708 @default.
• W4376613426 hasConceptScore W4376613426C530470458 @default.
• W4376613426 hasConceptScore W4376613426C71924100 @default.
• W4376613426 hasIssue "1" @default.
• W4376613426 hasLocation W43766134261 @default.
• W4376613426 hasOpenAccess W4376613426 @default.
• W4376613426 hasPrimaryLocation W43766134261 @default.
• W4376613426 hasRelatedWork W2006992144 @default.
• W4376613426 hasRelatedWork W2137228442 @default.
• W4376613426 hasRelatedWork W2343994751 @default.
• W4376613426 hasRelatedWork W2778335622 @default.
• W4376613426 hasRelatedWork W3031648518 @default.
• W4376613426 hasRelatedWork W3040632016 @default.
• W4376613426 hasRelatedWork W3120804187 @default.
• W4376613426 hasRelatedWork W3174405896 @default.
• W4376613426 hasRelatedWork W3207233484 @default.
• W4376613426 hasRelatedWork W4286512930 @default.
• W4376613426 hasVolume "8" @default.
• W4376613426 isParatext "false" @default.
• W4376613426 isRetracted "false" @default.
• W4376613426 workType "article" @default.